Case: Talis Biomedical Corporation
Venue: NDCA
Class Period: On behalf of investors that purchased or otherwise acquired Talis common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 2021 IPO.
Lead Plaintiff Deadline: 3/8/2022
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NEW YORK, NY – January 10, 2022 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS), a company that develops diagnostic tests for infectious diseases.  

Talis conducted its initial public offering in February 2021 by selling 15,870,000 shares of common stock at a price of $16 per share (the “IPO”).  A complaint has been filed on behalf of investors that purchased or otherwise acquired Talis common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 2021 IPO.

According to the complaint, on March 8, 2021, Talis announced that it had withdrawn its EUA application for the Talis One COVID-19 test.  In a press release, the Company revealed that “[i]n late February, the FDA informed the company that it cannot ensure the comparator assay used in the primary study has sufficient sensitivity tosupport Talis’s EUA application.” As a result, Talis “intends to initiate its previously planned clinical validation study in a point-of-care environment” to submit its EUA application “early in the second quarter of 2021.” This study “was designed with a different comparator study, which Talis believes will address the FDA’s concerns.” 

On this news, the Company’s stock price fell $1.80, more than 12%, to close at $12.85 per share on March 8, 2021.  

Then, on August 10, 2021, Talis revealed that its “development timelines have been extended by delays in the launching of [Talis’s] COVID-19 test and manufacturing scale.” As a result, Talis “expect[s] to see [its] first meaningful revenue ramp in 2022.” 

On this news, the Company’s stock price fell $0.58, or about 6.5%, to close at $8.39 per share on August 11, 2021. 

Further, on August 30, 2021, after the market closed, Talis announced that its Chief Executive Officer, Brian Coe, had “stepped down” as President, CEO, and Director.

On this news, the Company’s stock price fell $1.00, about 11%, to close at $8.06 per share on August 31, 2021.

On November 15, 2021, Talis announced that Brian Blaser was appointed asPresident, Chief Executive Officer, and Director of Talis effective December1, 2021. However, a week after his appointment, on December 8, 2021, Talisannounced that Brian Blaser had stepped down from his positions. 

On this news, the Company’s stock price fell $0.55 per share, or more than 11%, to close at $4.28 per share on December 8, 2021.

If you are a member of the proposed Class, you may move the court no later than March 8, 2022 to serve as a lead plaintiff for the purported class.  You need not seek to become a lead plaintiff in order to share in any possible recovery.  If you would like to discuss the complaint or our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling (646) 315-9003.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, your rights, or your interests, please contact: 

Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(212) 687-1980
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it